Regulatory Concerns. Notwithstanding any other provision to the contrary contained in this Agreement, the ability of the Administrative Agent to (i) transfer record ownership of the Pledged Stock into the name of the Administrative Agent or its nominee pursuant to Section 7 hereof, (ii) vote and give consents, ratifications and waivers with respect to the Pledged Stock pursuant to Section 7 hereof and (iii) sell the Pledged Stock pursuant to Section 8 or 9 hereof is subject to the Administrative Agent or its nominee (a) obtaining, to the extent necessary under applicable laws and regulations, the prior approval of the FCC, any PUC or any other Governmental Authority having jurisdiction with respect to any Issuer and its Subsidiaries and (b) making any additional filings, reports or notifications required with respect to the exercise by the Administrative Agent of the powers specified in clauses (i), (ii) and (iii) of this section.

Regulatory Concerns. (a) Purchaser acknowledges and understands that notwithstanding anything to the contrary contained herein if the Commission at any time determines that Purchaser is unsuitable to hold Shares or other securities of Seller, then until such Shares or other securities are owned by persons other than Purchaser, (i) Seller shall not be required or permitted to pay any dividend or interest with regard to such Shares or other securities, (ii) the holder of such Shares or other securities shall not be entitled to vote on any matter as a holder of such Shares or other securities, and such Shares or other securities shall not for any purposes be included in the Shares or other securities of the Company entitled to vote, and (iii) Seller shall not pay any remuneration in any form to the holder of such Shares or other securities.

Regulatory Concerns. 89bio may terminate the Agreement immediately upon written notice to Provider pursuant to Section 11.2(g), Section 11.2(h) or if Provider is subject to any Regulatory Authority warning letter or sanction related to the Facility.

Regulatory Concerns. Buyer's business, and the electrical and natural gas industries generally, is subject to regulation at both the federal and state levels. As a result of deregulation, Buyer has fewer federal and state laws and regulations to comply with than has traditionally been the case. However, Buyer continuously reviews its procedures and policies for compliance with laws and regulations applicable to its operations and believes that it is in substantial compliance with all such material laws and regulations. Furthermore, while the costs of compliance with such laws and regulations have not been material to Buyer, there can be no assurance that such costs will not become more significant to Buyer in the future. In addition, the failure to comply with any of the laws or regulations imposed upon Buyer could result in fines or the suspension or revocation of its license to sell electricity or natural gas, which could have a material adverse impact upon Buyer.

Regulatory Concerns. In the event that a Participant, assignee, or Person holding a sub-participation (a “Holder”) is determined to be a Disqualified Holder, the Seller shall have the right to repurchase such Holder’s interests in a Loan by payment to such Holder of the outstanding principal balance of such interests, together with accrued but unpaid interest thereon, held by such Holder. IN WITNESS OF THE ABOVE AGREEMENTS, the Parties have caused this document to be executed by their respective representatives as of the date specified in the first sentence above. GREAT LAKES GAMING OF MICHIGAN, LLC Per: Name: Title: [PARTICIPANT]: Per: Name: Title: CERTIFICATION BY LAKES ENTERTAINMENT, INC. To: [PARTICIPANT] Lakes Entertainment, Inc. (“LACO”), a Minnesota corporation, hereby represents and warrants that, as of the Closing Date no Event of Default by the Seller and, to LACO’s knowledge, by the Obligor has occurred or is continuing with respect to the Development Agreement and the Management Agreement. Capitalized terms that are not otherwise defined in this certification shall have the meanings given in the Master Participation Agreement dated March 2, 2007, between you and Great Lakes Gaming of Michigan, LLC. LAKES ENTERTAINMENT, INC. Per: Name: Title: EXHIBIT A FORM OF CONSENT AND ACKNOWLEDGMENT Pokagon Gaming Authority hereby consents to the Master Participation Agreements to which this consent is attached (the “Participation Agreements”) and the transactions contemplated thereby, and hereby acknowledges and confirms that (i) each of the Loans has been fully funded, and the Seller has no obligation to make any further advances or extend any other financial accommodations under the Loans and Notes, (ii) interest has accrued on the Loan evidenced by the Third Amended and Restated Transition Loan Note from and after July 8, 2001, and (iii) this consent is given pursuant to the written approval of the Pokagon Gaming Authority, the entity designated pursuant to resolution and ordinance of the “Pokagon Council” (as defined in the Development Agreement and the Management Agreement), as evidenced by the Assignment and Assumption Agreement and the Pokagon Gaming Authority Ordinance duly enacted by the Pokagon Council (as contemplated by the Development Agreement and the Management Agreement); and otherwise complies with the requirements of Section 15.18 of the Development Agreement and Section 14.1 of the Management Agreement. This Consent shall not give rise to liability by the Pok...

Regulatory Concerns. Cypress further represents that there have been no comments, either oral or in writing, raised by the Securities and Exchange Commission or any state securities regulatory agency that have not been responded to and resolved to the satisfaction of such regulator as of the date hereof.

Related to Regulatory Concerns

Regulatory Cooperation In connection with any foreclosure, collection, sale or other enforcement of Liens granted to the Administrative Agent in the Collateral Documents, Parent will, and will cause its Restricted Subsidiaries to, reasonably cooperate in good faith with the Administrative Agent or its designee in obtaining all regulatory licenses, consents and other governmental approvals necessary or (in the reasonable opinion of the Administrative Agent or its designee) reasonably advisable to conduct all aviation operations with respect to the Collateral and will, at the reasonable request of the Administrative Agent and in good faith, continue to operate and manage the Collateral and maintain all applicable regulatory licenses with respect to the Collateral until such time as the Administrative Agent or its designee obtain such licenses, consents and approvals, and at such time Parent will, and will cause its Restricted Subsidiaries to, cooperate in good faith with the transition of the aviation operations with respect to the Collateral to any new aviation operator (including, without limitation, the Administrative Agent or its designee).
Regulatory Issues 3.3.1 The Licensee shall be solely responsible for determining which jurisdictions they choose to market to and receive xxxxxx from.
Regulatory Reporting Ultimus agrees to provide reports to the federal and applicable state authorities, including the SEC, and to the Funds’ Auditors. Applicable state authorities are those governmental agencies located in states in which the Fund is registered to sell shares.
Regulatory Applications (a) Sky and Metropolitan and their respective Subsidiaries shall cooperate and use their respective reasonable best efforts to prepare, within 45 days of the execution of this Agreement, all documentation and requests for regulatory approval, to timely effect all filings and to obtain all permits, consents, approvals and authorizations of all third parties and Governmental Authorities and Regulatory Authorities necessary to consummate the transactions contemplated by this Agreement. Each of Sky and Metropolitan shall have the right to review in advance, and to the extent practicable each will consult with the other, in each case subject to applicable laws relating to the exchange of information, with respect to, and shall be provided in advance so as to reasonably exercise its right to review in advance, all material written information submitted to any third party or any Governmental Authority or Regulatory Authority in connection with the transactions contemplated by this Agreement. In exercising the foregoing right, each of the parties hereto agrees to act reasonably and as promptly as practicable. Each party hereto agrees that it will consult with the other party hereto with respect to the obtaining of all material permits, consents, approvals and authorizations of all third parties and Governmental Authorities or Regulatory Authorities necessary or advisable to consummate the transactions contemplated by this Agreement and each party will keep the other party apprised of the status of material matters relating to completion of the transactions contemplated hereby.
Regulatory Consents The waiting period applicable to the consummation of the Merger under the HSR Act shall have expired or been earlier terminated.
Regulatory Capital The Company and the Bank are “well-capitalized” as such term is defined in 12 C.F.R. 225.2 and 12 C.F.R. 325.103, respectively.
Regulatory Examinations The Sub-Advisor will cooperate promptly and fully with the Advisor and/or the Trust in responding to any regulatory or compliance examinations or inspections (including information requests) relating to the Trust, the Fund or the Advisor brought by any governmental or regulatory authorities having appropriate jurisdiction (including, but not limited to, the SEC).
Cooperation with Regulatory Authorities The parties to this Agreement each agree to cooperate in a reasonable manner with each other in the event that any of them should become involved in a legal, administrative, judicial or regulatory action, claim, or suit as a result of performing its obligations under this Agreement.
Regulatory Authorities Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, the Company and its subsidiaries: (i) are in compliance in all material respects with all statutes, rules, regulations, ordinances, orders and decrees applicable to the ownership, testing, in humans or laboratory models, development, manufacture, formulation, packaging, processing, recordkeeping, use, distribution, marketing, labeling, promotion, sale, price reporting, reimbursement, storage, import, export or disposal of any product manufactured or distributed by or for the Company or any of its subsidiaries (“Applicable Laws”), except where the failure to so comply would not, individually or in the aggregate, result in a Material Adverse Effect; (ii) to the knowledge of Company and its subsidiaries, have not, either voluntarily or involuntarily, disclosed to any governmental authority any violations of Applicable Laws, except such as would not, individually or in the aggregate, result in a Material Adverse Effect; (iii) have not received any Food and Drug Administration (“FDA”) Form 483 or any foreign counterpart thereof, warning letter, clinical hold notice or untitled letter from the FDA, any Institutional Review Board (as defined by federal regulation at 21 CFR Section 56.102(g)) or any other governmental authority alleging or asserting noncompliance with any Applicable Laws or any licenses, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”), except such as would not, individually or in the aggregate, result in a Material Adverse Effect; (iv) have not received notification of nor have reason to believe that any audits by a governmental authority have resulted in a determination that any of their respective products have been improperly reimbursed, except such audits and determinations as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; (v) possess all Authorizations (including, without limitation, exemptions under any Investigational Device Exemption or Investigational New Drug Application, as described at 21 CFR Sections 312 and 812, and approvals of any Institutional Review Board), which are in full force and effect, required for the conduct of their respective businesses (and such Authorizations are valid and in full force and effect) and are not in violation of any term of any such Authorizations, except where the failure to possess such Authorization or the violation of such Authorization would not, individually or in the aggregate, result in a Material Adverse Effect; (vi) have not received written notice of any pending or threatened claim, suit, proceeding, clinical hold, hearing, enforcement, audit, investigation, arbitration, suspension, debarment or exclusion from any governmental authority or Institutional Review Board alleging that any of their respective operations or activities is in violation of any Applicable Laws or Authorizations and the Company has no knowledge or reason to believe that any such governmental authority, Institutional Review Board or other non-governmental authority is considering any such claim, suit, proceeding, clinical hold, hearing, enforcement, audit, investigation, arbitration, suspension, debarment or exclusion except for any such claims, suits, proceedings, clinical holds, hearings, enforcements, audits, investigations, arbitrations, suspensions, debarments or exclusions that would not, individually or in the aggregate, result in a Material Adverse Effect; (vii) have not received written notice that any governmental authority or Institutional Review Board has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and the Company has no knowledge or reason to believe that any such governmental authority is considering such action, except for any such actions that would not, individually or in the aggregate, result in a Material Adverse Effect; (viii) have, or have had on their behalf, filed, declared, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as are required by any Applicable Laws or Authorizations, except where the failure to so file, declare, obtain, maintain or submit would not, individually or in the aggregate, result in a Material Adverse Effect and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission); and (ix) have not, either voluntarily or involuntarily, initiated, conducted or issued, or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, warning, “dear doctor” letter or investigator notice relating to an alleged lack of safety or efficacy of any product or product candidate, any alleged product defect, or violation of any material Applicable Laws or Authorizations and the Company is not aware of any facts that would cause the Company or any of its subsidiaries to initiate any such notice or action and the Company has no knowledge or reason to believe that any governmental authority, Institutional Review Board or other non-governmental authority intends to initiate any such notice or action, except for any such notices or actions that would not, individually or in the aggregate, result in a Material Adverse Effect. Any clinical trials conducted by or on behalf of the Company or any of its subsidiaries that are described in the Registration Statement, the General Disclosure Package or the Prospectus were and, if still pending, are being conducted in compliance in all material respects with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all applicable federal, state, local and foreign laws, rules and regulations, including, but not limited to, the Federal Food, Drug, and Cosmetic Act and implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58 and 312. Any descriptions of studies, tests and preclinical and clinical trials, including any related results and regulatory status, contained in the Registration Statement, the General Disclosure Package or the Prospectus are, and will be, accurate and complete in all material respects. The Company is not aware of any studies, tests or trials the results of which reasonably call into question in any material respect the clinical trial results described or referred to in the Registration Statement, the General Disclosure Package or the Prospectus. Neither the Company nor any of its subsidiaries has received any written notices or other correspondence from the FDA, an Institutional Review Board or other governmental agency requiring or recommending the termination, suspension or material modification of any clinical trials conducted by, or on behalf of, the Company or any of its subsidiaries or in which the Company or any of its subsidiaries has participated.
Regulatory Changes If any Lender shall determine that (a) any change in any Legal Requirement (including any new Legal Requirement) after the date hereof shall directly or indirectly (i) reduce the amount of any sum received or receivable by such Lender with respect to the Loan or the Letters of Credit or the return to be earned by such Lender on the Loan or the Letters of Credit, (ii) impose a cost on such Lender or any Affiliate of such Lender that is attributable to the making or maintaining of, or such Lender’s commitment to make, its portion of the Loan or the Letters of Credit, or (iii) require such Lender or any Affiliate of such Lender to make any payment on, or calculated by reference to, the gross amount of any amount received by such Lender under any Credit Document, and (b) such reduction, increased cost or payment shall not be fully compensated for by an adjustment in the Applicable Rate or the Letter of Credit fees, then, within 15 days after the receipt by the Company of a certificate from such Lender setting forth why it is claiming compensation under this Section 3.8 and computations (in reasonable detail) of the amount thereof, the Company shall pay to such Lender such additional amounts as such Lender determines will, together with any adjustment in the Applicable Rate, fully compensate for such reduction, increased cost or payment, together with interest on such amount from the 15th day after receipt of such certificate until payment in full thereof at the Overdue Rate. The determination by such Lender of the amount to be paid to it and the basis for computation thereof hereunder shall, in the absence of demonstrable error, be conclusive. In determining such amount, such Lender may use any reasonable averaging and attribution methods. The Company shall be entitled to replace any such Lender in accordance with Section 13.3.

Regulatory Concerns Sample Clauses

Filter & Search

Related Clauses

Parent Clauses

Related to Regulatory Concerns